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Background-—Experimental studies demonstrated that glutathione peroxidase 3 (GPx3), an antioxidant enzyme that catabolizes
hydrogen peroxide, protects against thrombosis. Little is known about its role in cardiovascular disease.
Methods and Results-—A prospective cohort study was conducted in 909 atrial fibrillation patients. Serum activities of GPx3,
superoxide dismutase (SOD), and catalase were measured at baseline to assess the risk of cardiovascular events during a mean
follow-up of 43.4 months (3291 person-years). Serum Nox2 and urinary excretion of 11-deydro-thromboxane B2 were also
measured. During follow-up 160 cardiovascular events occurred (4.9%/year). Significantly lower values of GPx3 (P<0.001) and
SOD (P=0.037) were detected in patients with, compared to those without, cardiovascular events. A lower survival rate was
observed in patients with GPx3 (P<0.001) and SOD (P=0.010) activities below the median, as compared to those above. In a fully
adjusted Cox regression model, GPx3 was the only antioxidant enzyme predictor of cardiovascular events (hazard ratio 0.647, 95%
confidence interval 0.524-0.798, P<0.001). GPx3 was inversely associated with urinary 11-dehydro-thromboxane B2 (B 0.337,
P<0.001) and serum Nox2 (B: 0.423, P<0.001). GPx3 activity progressively decreased with decades of age (P<0.001), with a
progressive reduction in people aged ≥70 years.
Conclusions-—This study provides evidence that a low antioxidant status, as depicted by reduced levels of GPx3, increases the risk
of cardiovascular events in patients with atrial fibrillation. The age-related decline of GPx3 may represent a mechanism for the
enhanced cardiovascular risk in the elderly population. ( J Am Heart Assoc. 2016;5:e003682 doi: 10.1161/JAHA.116.003682)
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C ardiovascular disease is the main cause of morbidity andmortality in the Western countries. Aging largely con-
tributes to this phenomenon, as it is independently associated
with an increased risk of coronary and cerebrovascular
disease.1 As the size of the elderly population steadily
increases in the next 2 to 3 decades, the number of subjects
expected to experience cardiovascular disease, will substan-
tially increase in the next future.
There is a growing body of experimental evidence in
support of the free radical theory of aging, suggesting that
oxidative stress is implicated in vascular damage, atheroscle-
rosis, and its sequelae.2 According to this theory, the
formation of reactive oxygen species increases with age,
ultimately resulting in damage to cells and their components
such as DNA, lipids, and proteins. The balance between
enzymes eliciting the formation of reactive species and
antioxidants seems to have a negative impact on morbidity
and life span. The relationship among aging, oxidative stress,
and cardiovascular disease is essentially based on in vitro and
experimental studies,3 while data in humans are still unde-
fined. A previous study4 demonstrated that glutathione
peroxidase 1 is predictive of cardiovascular events, suggest-
ing that a low antioxidant status predisposes to poor vascular
outcomes. However, the relationship between low glutathione
peroxidase activity and oxidative stress, and the impact of
aging on antioxidant status are still unclear. To address these
issues, we investigated a population affected by atrial
fibrillation (AF), which is closely related to oxidative stress5
and aging. In particular, previous studies showed that
oxidative stress related to the activity of NADPH oxidase
(Nox) is increased in experimental atrial pacing-induced AF6
and associated with an increased risk of postoperative AF
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after cardiac surgery.7 Moreover, Nox2 activity has been
shown to be predictive of cardiovascular events in AF.5
Despite the many efforts, the overall thrombotic risk is still
high in AF, and, therefore, the clinical need remains to identify
patients high-risk patients. Older age may contribute to lower
antioxidant status, but the relationship between older age and
antioxidant status in patients with AF is not well established.
To this purpose, we measured the activity of three antioxidant
enzymes, namely glutathione peroxidase 3 (GPx3) and
catalase, which catabolize hydrogen peroxide,8 and superox-
ide dismutase (SOD), which converts superoxide anion to
hydrogen peroxide,9 in an AF population prospectively
followed up for about 3 years to assess the incidence of
cardiovascular disease such as stroke, myocardial infarction,
and cardiovascular death.
Methods
We performed a prospective single-center cohort study
including 990 patients with nonvalvular AF who were referred
to the Atherothrombosis Center of the Department of Internal
Medicine and Medical Specialties of Sapienza University of
Rome, from September 2007 to October 2015. All patients
were treated with oral vitamin K antagonists (INR range 2.0-
3.0) initially according to CHADS2 score, and then to
CHA2DS2 VASc score.
Exclusion criteria included the presence of prosthetic heart
valves, cardiac stent placement or cardiac revascularization in
the previous year, severe cognitive impairment, chronic
infectious diseases, autoimmune systemic diseases, and
active cancer.
Baseline medical history and anthropometric data were
recorded, and blood and urine samples were collected.
Electrocardiography and echocardiography were also per-
formed. Cardiovascular risk factors were defined according to
international criteria: arterial hypertension as repeatedly
elevated blood pressure (≥140/≥90 mm Hg) or taking anti-
hypertensive drugs10; diabetes as a casual plasma glucose
≥200 mg/dL (11.1 mmol/L), or fasting plasma glu-
cose≥126 mg/dL (7.0 mmol/L), or 2-hour plasma glucose
≥200 mg/dL (11.1 mmol/L) during an oral glucose tolerance
test or taking antidiabetic drugs11; heart failure as the
presence of signs and symptoms typical of congestive heart
failure or reduced ejection fraction (≤40%).12
The primary endpoint of the study was a composite of
cardiovascular events including fatal/nonfatal myocardial
infarction or ischemic stroke, cardiac revascularization, car-
diovascular death, and transient ischemic attack.
Diagnosis of myocardial infarction was made according to
the definition proposed by the Joint ESC/ACCF/AHA/WHF
Task Force.13 The occurrence of ischemic stroke was
determined on clinical manifestations and confirmed by
radiological findings; transient ischemic attack was defined
according to the Classification of Cerebrovascular Diseases
III.14 If a patient died within 4 weeks of myocardial infarction
or ischemic stroke, these events were recorded as fatal
myocardial infarction or fatal ischemic stroke, respectively.
Death was classified as cardiovascular unless an unequivocal
noncardiovascular cause of death was identified. Cardiovas-
cular death included sudden death, progressive congestive
heart failure, and procedure-related death.
Data on cardiovascular events were prospectively collected
during follow-up, and only the first event was used for the
analysis.
All patients provided a written informed consent before
being included in the study. The study protocol was approved
by the local ethical board of Sapienza-University of Rome (no.
1306/2007) and was conducted according to the principles
of the Declaration of Helsinki.
Laboratory Analyses
A blood sample was collected for each AF patient in the
morning after overnight fasting. Samples were centrifuged
immediately after collection, aliquoted, and stored at 80°C
until use.
Glutathione peroxidase 3 activity was measured in serum
by Colorimetric Assay Kit (Abcam, Cambridge, UK). In this
assay, glutathione peroxidase reduces the probe cumene
hydroperoxide while it converts reduced glutathione to its
oxidized form, glutathione disulfide. The generated oxidized
glutathione is converted into reduced glutathione by
glutathione reductase, using nicotinamide adenine dinu-
cleotide phosphate as reducing agent. GPx3 activity is
proportional to the decrease in absorbance of nicotinamide
adenine dinucleotide phosphate at 340 nm. One unit (U) of
glutathione peroxidase is defined as the amount of enzyme
that will cause the oxidation of 1 nmole of nicotinamide
adenine dinucleotide phosphate (from NADPH to NADP+)
per minute at 25°C. GPx3 activity was expressed as units
per milliliter. Intra- and interassay coefficients of variation
(CVs) were 4.0% and 6.0%, respectively; sensitivity was
0.5 mU/mL. To assess temporal variability we measured
the activity of GPx3 in 20 patients twice in 3 weeks and
found no significant differences between the 2 determina-
tions (P=0.279).
SOD activity was measured in serum samples by Activity
Kit (Arbor Assay, Ann Arbor, MI). Samples were incubated with
the substrate followed by xanthine oxidase reagent. The
xanthine oxidase generates superoxide in the presence of
oxygen, which converts a colorless substrate into a colored
product. The colored product was read at 450 nm. SOD
activity was expressed as units per milliliter. Intra- and
interassay CVs were 4.6% and 6.1%, respectively.
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Catalase activity was measured in serum samples with
Catalase Activity Kit (Arbor Assay). Hydrogen peroxide was
added to samples and standards. In the presence of hydrogen
peroxide, horseradish peroxidase–conjugated antibody con-
verts the colorless substrate into a colored product. The
colored product was read at 560 nm. Increasing levels of
catalase in the samples cause a decrease in H2O2. Catalase
activity was expressed as units per milliliter. Intra- and
interassay CVs were 3.5% and 9.8%, respectively.
The excretion of urinary 11-dehydro-thromboxane B2 was
measured by an ELISA commercial kit (Cayman, Ann Arbor,
MI). Data were expressed as nanograms per milligram urinary
creatinine. Intra- and interassay CVs were 4.0% and 3.6%,
respectively.
Serum Nox2 activity was assessed by serum levels of Nox2
derived peptide, a marker of Nox2 activation, by ELISA
method. The peptide was recognized by the specific mono-
clonal antibody against the amino acidic sequence (224–268)
of the extramembrane portion of Nox2 that was released in
the medium on cell activation. Values were expressed as
picograms per milliliter. Intra- and interassay CVs were 5.2%
and 6%, respectively.
Statistical Analysis
Categorical variables were reported as counts (percentage).
The normal distribution of parameters was assessed by
Kolmogorov-Smirnov test. Continuous variables were
expressed as mean  standard deviation or median and
interquartile range. Independence of categorical variables was
tested with the chi-squared test. Student unpaired t test and
Pearson product-moment correlation analyses were used for
normally distributed continuous variables. Appropriate non-
parametric tests (Mann-Whitney U test and Spearman rank
correlation test) were used for all the other variables. Kruskal-
Wallis test was used to compare groups. The cumulative
incidence of cardiovascular events was estimated using a
Kaplan-Meier product-limit estimator for each antioxidant
enzyme of interest. Survival curves were formally compared
using the log-rank test. Cox proportional hazards analyses
were used to calculate the adjusted relative hazards of
cardiovascular events by each clinical variable. We built 4
different models, 1 for each of the above-mentioned antiox-
idant enzymes, and 1 fully adjusted model including all
predictors. In addition to antioxidant enzymes, the
Table 1. Baseline Characteristics of the Study Cohort and Occurrence of Cardiovascular Events
Variables
Overall Cardiovascular Events
P Value(n=909) No (n=749) Yes (n=160)
Age, y 73.58.2 72.88.3 76.77.2 <0.001
Women, % 43.1 43.4 41.9 0.792
Smokers, % 9.5 9.5 9.4 0.967
CHA2DS2-VASc score* 4.0 [3.0-4.0] 3.0 [2.0-4.0] 4.0 [3.0-5.0] <0.001
Arterial hypertension, % 94.6 94.4 95.6 0.700
Diabetes mellitus, % 19.9 17.9 29.4 0.001
Heart failure, % 16.1 13.6 27.5 <0.001
Ejection fraction, % 53.59.0 54.18.7 50.79.9 <0.001
History of stroke/transient
ischemic attack, %
14.5 11.9 26.9 <0.001
History of myocardial
infarction/cardiac
revascularization, %
25.1 21.4 42.5 <0.001
Antiplatelet drugs, % 19.1 17.5 26.9 0.008
Statins, % 41.3 41.7 39.4 0.658
Glutathione peroxidase 3, U/mL* 20.0 [10.0–34.0] 21.0 [12.0–34.0] 12.0 [6.0–21.0] <0.001
Superoxide dismutase, U/mL* 2.2 [1.4–3.2] 2.3 [1.4–3.2] 2.1 [1.5–3.2] 0.037
Catalase, U/mL* 25.0 [20.0–32.0] 25.0 [20.0–32.0] 26.0 [21.0–31.0] 0.954
Thromboxane B2, ng/mg creatinine
† 120.0 [70–196.5] 120.0 [68.5–186.0] 150.0 [90.0–283.0] <0.001
Serum Nox2, pg/mL‡ 10.0 [7.0–20.0] 10.0 [6.0–19.0] 13.0 [8.0–23.0] 0.002
*Data expressed as median and interquartile range.
†Data available in 852 patients.
‡Data available in 742 patients.
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multivariable analyses were performed with the following
prespecified variables entered as covariates: age, female sex,
smoking, arterial hypertension, diabetes, history of myocardial
infarction, history of stroke/transient ischemic attack, heart
failure, and treatment with antiplatelet drugs and statins.
Multivariable linear regression analysis was used to determine
factors associated with serum levels of GPx3.
Two distinct linear regression models were used to
investigate the association of GPx3 with Nox2 and thrombox-
ane B2, respectively.5,15
Statistical significance was set at a P value <0.05. All tests
were 2-tailed, and analyses were performed using computer
software packages (SPSS-18.0, SPSS Inc, Chicago, IL).
Results
According to the exclusion criteria, 59 patients were
excluded, and 22 refused to be included in the study.
Thus, 909 AF patients composed the final cohort.
Antioxidant Enzymes and Cardiovascular Events
Mean follow-up was 43.4 (29.6) months, yielding 3291
person-years of observation; overall, 160 cardiovascular
events were registered (4.9%/year): 19 nonfatal and 16 fatal
myocardial infarctions, 19 cardiac revascularizations, 24
nonfatal and 12 fatal ischemic strokes, 5 transient ischemic
attacks, and 65 cardiovascular deaths. Patients with cardio-
vascular events had lower GPx3 and SOD activities compared
to patients free from events (see Table 1).
After the cohort had been divided according to the
median value of GPx3, 113 cardiovascular events were in the
group below and 47 in the group above the median (Log-rank
test for GPx3 below the median, P<0.001; see Figure 1A).
Similar results were obtained with SOD (P=0.010), with 94
cardiovascular events in the group below and 66 in the
group above the median (see Figure 1B). Conversely, cata-
lase levels were not associated with cardiovascular events
(P=0.673).
Cox regression analysis showed that log GPx3 along with
age, diabetes, history of stroke/transient ischemic attack,
and myocardial infarction predicted cardiovascular events
(see Table 2, Model 1). Similar results were found with log
SOD (see Table 2 Model 2) but not with catalase (see
Table 2, Model 3). In a fully adjusted model, only log GPx3
persisted as predictor of cardiovascular events (see Table 2,
Model 4).
Determinants of GPx3 Activity
Because GPx3 was the strongest predictive antioxidant
enzyme we investigated factors affecting its serum levels.
Gpx3 was weakly correlated with SOD (Rs 0.269, P<0.001)
and not correlated with catalase (Rs 0.018, P=0.581).
A linear regression analysis showed an inverse association
for age and heart failure, and smoking was positively
associated (see Table 3). GPx3 activity was also inversely
correlated with CHA2DS2 VASc score (Rs 0.187, P<0.001).
Given that age was the most important determinant of GPx3,
we further investigated the relationship between age and
GPx3 by dividing our population into decades (ie, 50-60, 61-
70, 71-80, >80 years). We found a progressive decrease of
A
B
Figure 1. Kaplan-Meier curves show estimates of cardiovascu-
lar events according to the median value of glutathione perox-
idase 3 (A), and superoxide dismutase (B).
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GPx3 across decades (Kruskal-Wallis test, P<0.001, see
Figure 2).
GPx3 Activity and Oxidative Stress
To explore the relationship between GPx3 activity and
oxidative stress, we measured the activity of serum Nox2.
We found that GPx3 and Nox2 were inversely correlated (Rs
0.434, P<0.001). In a second model of linear regression
analysis including Nox2 as covariate, we found that Nox2 and
GPx3 were independently and inversely associated (B
0.423, P<0.001; Table 4).
Finally, when we investigated the relationship between
GPx3 and urinary thromboxane B2, we found an inverse
association (Rs 0.365, P<0.001). Thromboxane B2 and Nox2
were also mutually correlated (Rs 0.492, P<0.001). In a linear
regression analysis, thromboxane B2 (B 0.337, P<0.001),
along with age and heart failure, was inversely associated with
GPx3 (Table 4).
Discussion
The study provides evidence of an inverse relationship
between GPx3 activity and cardiovascular events in a
Table 2. Adjusted Hazard Ratios, Based on Cox Proportional
Hazards Models
P Value Hazard Ratio 95% CI
Model 1 (glutathione peroxidase 3)
Age <0.001 1.072 1.048 1.096
Female sex 0.177 0.796 0.572 1.109
Arterial hypertension 0.860 1.073 0.491 2.344
Diabetes mellitus 0.009 1.595 1.126 2.258
Smoking 0.066 1.673 0.966 2.896
Heart failure 0.159 1.312 0.899 1.914
History of stroke/transient
ischemic attack
0.002 1.773 1.244 2.526
History of myocardial
infarction/cardiac
revascularization
0.003 1.687 1.191 2.930
Antiplatelet drugs 0.496 1.132 0.792 1.617
Statins 0.549 1.108 0.792 1.551
Log-glutathione
peroxidase 3
<0.001 0.625 0.515 0.759
Model 2 (superoxide dismutase)
Age <0.001 1.080 1.056 1.105
Female sex 0.242 0.822 0.591 1.142
Arterial hypertension 0.965 0.983 0.452 2.138
Diabetes mellitus 0.006 1.624 1.146 2.302
Smoking 0.176 1.455 0.845 2.507
Heart failure 0.054 1.448 0.993 2.110
History stroke/transient
ischemic attack
0.001 1.775 1.247 2.527
History of myocardial
infarction/cardiac
revascularization
0.001 1.765 1.246 2.501
Antiplatelet drugs 0.504 1.130 0.790 1.614
Statins 0.741 1.058 0.757 1.480
Log-Superoxide dismutase 0.009 0.640 0.458 0.894
Model 3 (catalase)
Age <0.001 1.082 1.058 1.107
Female sex 0.197 0.805 0.579 1.119
Arterial hypertension 0.882 0.943 0.435 2.044
Diabetes mellitus 0.009 1.593 1.125 2.256
Smoking 0.180 1.451 0.842 2.502
Heart failure 0.038 1.487 1.023 2.161
History stroke/transient
ischemic attack
0.001 1.799 1.264 2.562
History of myocardial
infarction/cardiac
Revascularization
0.002 1.759 1.240 2.495
Continued
Table 2. Continued
P Value Hazard Ratio 95% CI
Antiplatelet drugs 0.534 1.120 0.784 1.601
Statins 0.805 1.043 0.744 1.463
Log-Catalase 0.292 0.834 0.595 1.169
Model 4 (fully adjusted)
Age <0.001 1.072 1.048 1.096
Female sex 0.177 0.796 0.571 1.109
Arterial hypertension 0.870 1.067 0.488 2.332
Diabetes mellitus 0.008 1.606 1.133 2.277
Smoking 0.058 1.701 0.982 2.947
Heart failure 0.183 1.294 0.885 1.892
History stroke/transient
ischemic attack
0.001 1.789 1.255 2.550
History of myocardial
infarction/cardiac
revascularization
0.002 1.724 1.215 2.445
Antiplatelet drugs 0.452 1.147 0.803 1.639
Statins 0.637 1.085 0.773 1.522
Log-glutathione
peroxidase 3
<0.001 0.647 0.524 0.798
Log-superoxide dismutase 0.289 0.824 0.577 1.178
Log-catalase 0.157 0.781 0.555 1.100
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population affected by AF. In addition, GPx3 progressively
declines with aging, suggesting that the reduction of natural
antioxidants may be a factor predisposing to cardiovascular
complications in the elderly population.
Few studies investigated the predictive role of glutathione
peroxidases in patients at risk of cardiovascular events.
Among the 5 glutathione peroxidase isoforms, glutathione
peroxidase 1, contained in red cells, has been prospectively
analyzed in 636 patients with suspected coronary heart
disease. The study showed an inverse relationship between
the activity of the enzyme and the risk of cardiovascular events
in a follow-up period of 4.7 years.4 Among the glutathione
peroxidase isoforms, GPx3 is the only one detected in the
extracellular space and represents a major antioxidant in
plasma that serves to scavenge oxidant species. Human and
experimental studies demonstrated an important role of GPx3
in the thrombotic process.16,17 Thus, reduced activity of this
enzyme has been detected in patients at high risk of
thrombotic events. Furthermore, animals deficient in GPx3
showed enhanced platelet activation, platelet-rich thrombi,
and occluded vessels to a greater extent than wild-type
ones.17 The relationship between GPx3 and thrombosis is
likely to be attributable to hydrogen peroxide, which is a
stimulus for production of thromboxane A2,
18 a potent
aggregating molecule derived from COX1 activation. To best
of our knowledge, there is only 1 study that analyzed the
relationship between GPx3 and cardiovascular events in a
small cohort including 130 participants who died of cardio-
vascular events after 5 to 12 years of follow-up.19 This
retrospective study showed an inverse relationship between
glutathione peroxidase 3 activity and cardiovascular mortality
in subjects with low high-density lipoprotein values.19
In the context of AF, a low antioxidant status, as
demonstrated by an impaired GPx activity, has been described
to promote AF onset in an experimental model of atrial pacing
and in patients undergoing cardiac surgery.6,7 However, no
study investigated the relationship between GPx activity and
the incidence of cardiovascular disease in AF.
Indeed, this is the first prospective study investigating the
relationship between GPx3 and cardiovascular events in a
large cohort of patients with AF; this clinical setting is
characterized by a high risk of ischemic complications
including not only thromboembolic stroke but, as evidenced
by recent studies, myocardial infarction20,21 and peripheral
artery disease.22
Our analysis demonstrated an independent association
between GPx3 and the risk of cardiovascular events, after
Table 3. Linear Regression Analysis of Factors Associated With Log Glutathione Peroxidase 3 Levels
B SE b P Value 95% CI for B
Female sex 0.038 0.053 0.024 0.464 0.142 0.065
Age 0.017 0.003 0.179 <0.001 0.023 0.011
Diabetes 0.010 0.065 0.005 0.876 0.137 0.117
Smoking 0.229 0.088 0.085 0.010 0.056 0.402
Heart failure 0.194 0.072 0.091 0.007 0.335 0.053
Previous stroke/transient
ischemic attack
0.123 0.072 0.055 0.090 0.265 0.019
Previous myocardial
infarction/cardiac
revascularization
0.048 0.066 0.026 0.473 0.178 0.082
Arterial hypertension 0.051 0.113 0.015 0.652 0.171 0.274
Antiplatelet drugs 0.011 0.068 0.006 0.871 0.123 0.145
Statins 0.025 0.054 0.016 0.641 0.080 0.131
Figure 2. Decrease of glutathione peroxidase 3 across decades
of age.
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adjusting for potential confounding variables. Further confir-
mation of the role of an impaired antioxidant status in
facilitating cardiovascular disease was provided by the
analysis of SOD activity, although catalase showed no
predictive value on cardiovascular events. Among the 3
antioxidants, GPx3 showed the best predictive value, as it was
the only enzyme significantly associated with cardiovascular
events in the fully adjusted model.
In accordance with previous experimental study,11 we
found that GPx3 activity was inversely associated with urinary
excretion of thromboxane B2, a marker of in vivo platelet
activation,23 which suggests that the relationship between
GPx3 and cardiovascular events may be mediated by
enhanced platelet activation. In addition to platelet activation,
age was another strong predictor of GPx3 activity. This issue
has already been investigated by previous studies, with
equivocal results; of note, those studies measured the total
activity of the glutathione peroxidase family but not that of
specific isoforms. A novel finding of our study is that GPx3
progressively declines with advancing age with a significant
reduction in people aged ≥70 years, but the reason for such
an association cannot be deduced from the present study.
Endogenous mechanisms related to a progressive imbalance
between production of oxygen free radicals and antioxidant
defenses cannot be excluded, as suggested by the inverse
relationship between GPx3 and Nox2 activity. In addition,
Table 4. Linear Regression Analysis of Factors Associated With Log Glutathione Peroxidase 3 Levels
B Standard Error Beta P Value 95% CI for B
Model A* including log-soluble Nox2-derived peptide
Female sex 0.033 0.054 0.020 0.547 0.139 0.074
Age 0.012 0.003 0.119 <0.001 0.018 0.005
Diabetes 0.038 0.067 0.019 0.570 0.094 0.170
Smoking 0.196 0.089 0.073 0.028 0.021 0.372
Heart failure 0.170 0.072 0.079 0.019 0.311 0.028
Previous stroke/transient
ischemic attack
0.130 0.073 0.058 0.074 0.273 0.013
Previous myocardial
infarction/cardiac
revascularization
0.056 0.066 0.031 0.395 0.185 0.073
Arterial hypertension 0.077 0.115 0.022 0.505 0.302 0.149
Antiplatelet drugs 0.007 0.067 0.004 0.912 0.124 0.139
Statins 0.064 0.056 0.039 0.251 0.045 0.173
Log-serum Nox2 0.481 0.037 0.423 <0.001 0.555 0.408
Model B† including thromboxane B2
Female sex 0.017 0.051 0.011 0.739 0.118 0.084
Age 0.015 0.003 0.153 <0.001 0.021 0.008
Diabetes 0.017 0.063 0.009 0.790 0.107 0.141
Smoking 0.236 0.085 0.088 0.006 0.069 0.404
Heart failure 0.155 0.068 0.074 0.024 0.289 0.021
Previous stroke/transient
ischemic attack
0.105 0.070 0.048 0.132 0.243 0.032
Previous myocardial
infarction/cardiac
revascularization
0.015 0.064 0.008 0.815 0.140 0.110
Arterial hypertension 0.046 0.112 0.013 0.682 0.174 0.265
Antiplatelet drugs 0.034 0.066 0.017 0.601 0.164 0.095
Statins 0.057 0.052 0.035 0.281 0.046 0.159
Log-thromboxane B2 0.349 0.033 0.337 <0.001 0.414 0.285
*Data available in 742 patients.
†Data available in 852 patients.
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exogenous factors, such as nutrition, may be implicated in
this progressive decay of GPx3.
We also found a direct association between smoking and
GPx3 activity. This finding is apparently in contrast with 2
previous works that found no association between GPx
activity and smoking.6,7 The positive association between
smoking and GPx3 activity in our study may reflect a reactive
enhanced GPx3 activity to the increased production of
hydrogen peroxide, which is induced by smoking.24 However,
this association deserves further investigation.
The study has implications and limitations. The progressive
decay of GPx3 by aging and the interplay between GPx3 and
cardiovascular events may help understanding previous
experimental data indicating that aging-related thrombosis is
associated with enhanced platelet production of hydrogen
peroxide.25 However, a cause-effect relationship cannot be
established from this observational study. These findings may
help to identify a novel category of patients at high risk of
cardiovascular events who could benefit from specific antiox-
idant treatment. The present data can apply only to a white
population with AF, and results must be confirmed by a
multicenter study; also, another limitation is represented by
the lack of a control group of patients not affected by AF. The
role of heart failure in cardiovascular events may be
underestimated given its relatively low prevalence in our
cohort. Finally, even if GPx3 is the only described circulating
GPx isoform,26,27 we cannot exclude that other isoforms may
contribute to the circulating GPx activity.
In conclusion, the study provides evidence that GPx3
declines with aging, and its decline is associated with an
increased risk of cardiovascular events in patients with AF.
This finding might give novel insight into the mechanism
linking aging with cardiovascular risk.
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None.
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